映恩生物-B（09606）今日盘中大涨15.00%，股价一度触及232.8港元的历史新高，引发市场广泛关注。截至盘中，该股报226.4港元，成交额达1.75亿港元。
映恩生物是全球抗体偶联药物（ADC）领域的关键领跑者，专注于为癌症和自身免疫性疾病等患者研发ADC创新药物。公司拥有两款自主研发的核心产品，同时还有五项处于临床阶段的资产已获得美国食品药品管理局及中国国家药品监督管理局的研究用新药批准。其中，DB-1303对标Enhertu更具优势，全球领先；而DB-1311在治疗方面已初步展现潜力，有望引领小细胞肺癌（SCLC）与去势抵抗性前列腺癌（CRPC）用药突破。
国泰海通发布的最新研报进一步推动了映恩生物-B的股价上涨。该券商看好公司聚焦ADC新药研发的战略，以及产品达成的多项对外授权。研报预计2025-2027年公司收入将分别达到16.00亿、19.76亿和22.07亿元。基于综合绝对估值法及相对估值法，国泰海通给予映恩生物-B 300.70港元/股的目标价，并首次覆盖给予"增持"评级，显示出对公司未来发展的强烈信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.